Richard Donaldson - Er Therapeutics CEO
| PNGM Stock | USD 0.0001 0.00 0.00% |
CEO
Mr. Richard W. Donaldson was Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Director of Pengram Corporationrationration, since May 2, 2008. Mr. Donaldson is a self employed business consultant, involved in corporate management reorganizations, mergers and acquisitions for over 25 years. Mr. Donaldson is a former director and officer of numerous private and public companies, including Noront Resources Ltd., Aiviv Ventures Inc., Cherokee Minerals Corporationration, Canzona Minerals, Inc. and Renox Creek Petroleum Corporationration since 2008.
| Age | 85 |
| Tenure | 16 years |
| Address | 1200 Dupont Street, Bellingham, WA, United States, 98225 |
| Phone | 360-255-3436 |
| Web | https://pengramgold.com |
Er Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9491) % which means that it has lost $0.9491 on every $100 spent on assets. This is way below average. Er Therapeutics' management efficiency ratios could be used to measure how well Er Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Total Assets is likely to drop to about 283.4 K. In addition to that, Net Tangible Assets is likely to grow to about (96.1 K)Similar Executives
| Found 5 records | CEO Age | ||
| Donald Lindsay | Teck Resources Ltd | 62 | |
| Eduardo Bartolomeo | Vale SA ADR | 60 | |
| Jonathan MBA | Teck Resources Ltd | 47 | |
| Simon Clarke | American Lithium Corp | 58 | |
| Ana CabralGardner | Sigma Lithium Resources | 54 | |
Management Performance
| Return On Asset | -0.95 |
PNGM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Er Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.95 | ||||
| Current Valuation | 122.36 K | ||||
| Shares Outstanding | 58.26 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 143,650 X | ||||
| Net Income | (426.95 K) | ||||
| Cash And Equivalents | 650 | ||||
| Total Debt | 48.49 K | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.